Traders should monitor for potential downward pressure on ANIP shares, especially given the breadth of selling across the executive team. The absence of any offsetting insider buying and the concentration of sales among C-suite leaders may signal reduced confidence ahead of earnings or regulatory developments.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 9 $74.81entry
- T+1 · 9mo ago +1.54%α +1.72% · $75.96
- T+5 · 8mo ago −3.53%α −2.17% · $72.17
- T+20 · 8mo ago +6.23%α +9.03% · $79.47
- T+60 · 6mo ago −0.21%α −12.20% · $74.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven corporate insiders at ANI Pharmaceuticals sold shares in the past week, including five open-market sales totaling $1.23 million and four non-cash tax withholding transactions totaling $2.14 million. The selling involved key executives, including the CEO, CFO, and multiple SVPs, with open-market dispositions representing approximately 0.08% of the company's $1.6B market cap.
Key Financial Metrics
Key Facts
- Five open-market sales by senior executives totaling $1,228,501.87 in the past 7 days
- CEO Lalwani Nikhil did not sell shares directly but had 17,060 shares withheld for taxes ($1.26M value)
- CFO Carey and other SVPs also had shares withheld for taxes, adding $872,043.12 in non-cash dispositions
- Total insider share dispositions (cash + non-cash) in cluster: $3.37 million
- Open-market selling was distributed across multiple executives in established brands, rare disease, HR, and legal
- No insider purchases were reported in the cluster
Financial Impact
$1.23 million in open-market sales and $2.14 million in tax-related share surrenders over 7 days
Risk Factors
- Perception of insider pessimism due to coordinated timing of sales
- Potential for further selling if executives are exiting positions systematically
- Market reaction could amplify on light volume given the relatively small float typical in specialty pharma
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-ANIP-1773437352172 |
Track record
34 reports on ANIP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers